Andrew P Futreal
Overview
Explore the profile of Andrew P Futreal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Nguyen T, Li J, Song X, Fujimoto J, Little L, et al.
NPJ Precis Oncol
. 2024 Oct;
8(1):225.
PMID: 39369068
Lung Cancer remains the leading cause of cancer deaths in the USA and worldwide. Non-small cell lung cancer (NSCLC) harbors high transcriptomic intratumor heterogeneity (RNA-ITH) that limits the reproducibility of...
2.
Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers
Karpinets T, Mitani Y, Chang C, Wu X, Song X, Flores I, et al.
Sci Rep
. 2024 Jul;
14(1):16300.
PMID: 39009605
Adenoid cystic carcinoma (ACC) is a rare, usually slow-growing yet aggressive head and neck malignancy. Despite its clinical significance, our understanding of the cellular evolution and microenvironment in ACC remains...
3.
Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez F, Heeke S, et al.
Res Sq
. 2024 May;
PMID: 38798564
Studying lung adenocarcinoma (LUAD) early carcinogenesis is challenging, primarily due to the lack of LUAD precursors specimens. We amassed multi-omics data from 213 LUAD and LUAD precursors to identify molecular...
4.
Hao D, Han G, Sinjab A, Gomez-Bolanos L, Lazcano R, Serrano A, et al.
Cancer Discov
. 2022 Sep;
12(11):2626-2645.
PMID: 36098652
Significance: While TIBs are highly enriched in LUADs, they are poorly characterized. This study provides a much-needed understanding of the transcriptional, clonotypic states and phenotypes of TIBs, unraveling their potential...
5.
Saini N, Swoboda D, Greenbaum U, Ma J, Patel R, Devashish K, et al.
Blood Cancer Discov
. 2022 May;
3(5):385-393.
PMID: 35533245
Significance: Our study reveals that CH mutations, especially those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Further...
6.
Song X, Chang S, Seminario-Vidal L, Pulido A, Tordesillas L, Song X, et al.
Cancer Discov
. 2022 Mar;
12(5):1294-1313.
PMID: 35247891
Abstract: Cutaneous T-cell lymphoma (CTCL) is a rare cancer of skin-homing T cells. A subgroup of patients develops large cell transformation with rapid progression to an aggressive lymphoma. Here, we...
7.
Colbert L, El M, Lynn E, Bronk J, Karpinets T, Wu X, et al.
Cancer Immunol Res
. 2022 Jan;
10(2):259-271.
PMID: 35045973
Human papillomavirus (HPV) infection causes 600,000 new cancers worldwide each year. HPV-related cancers express the oncogenic proteins E6 and E7, which could serve as tumor-specific antigens. It is not known...
8.
Raghav K, Liu S, Overman M, Willett A, Knafl M, Fu S, et al.
Cancer Discov
. 2021 Jul;
11(11):2738-2747.
PMID: 34261675
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety...
9.
Karpinets T, Mitani Y, Liu B, Zhang J, Pytynia K, Sellen L, et al.
Clin Cancer Res
. 2021 May;
27(14):3960-3969.
PMID: 34011559
Purpose: Salivary gland carcinomas (SGCs) are pathologically classified into several widely diverse subtypes, of which adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), and salivary duct carcinoma (SDC) are the most...
10.
Mill C, Fiskus W, DiNardo C, Qian Y, Raina K, Rajapakshe K, et al.
Blood
. 2019 Apr;
134(1):59-73.
PMID: 31023702
RUNX1 transcription factor regulates normal and malignant hematopoiesis. Somatic or germline mutant RUNX1 (mtRUNX1) is associated with poorer outcome in acute myeloid leukemia (AML). Knockdown or inhibition of RUNX1 induced...